TG Therapeutics jumps as Q1 Briumvi sales top guidance

TG Therapeutics (NASDAQ:TGTX) shares rose ~26% in the premarket on Wednesday after the biotech exceeded expectations with its Q1 2024 revenue, as U.S. sales from its multiple sclerosis therapy, Briumvi, topped management’s guidance.

The company said that its anti-CD20 monoclonal antibody, launched in